缓解时间作为类风湿关节炎替代结局指标:2618例抗TNF新使用者的10年前瞻性研究
该研究基于捷克ATTRA-RA注册库,纳入2010年起2618例开始抗TNF治疗的RA患者并随访至2020年或停药,采用线性插值法计算缓解时间(TIR)。结果显示TIR与DAS28-CRP、SDAI、HAQ、PGA及PhGA相关(P<0.0001),且3个月和6个月的TIR对13个月和19个月时缓解(SDAI≤3.3)及无残疾(HAQ<0.5)的预测优于点缓解或持续缓解。
要点
- TIR通过两次连续DAS28-ESR线性插值估算就诊间未观测的疾病活动度。
- 治疗前6个月56%患者无缓解(TIR=0),22%达持续缓解(TIR=1)。
- 3个月和6个月TIR预测远期缓解与无残疾优于点缓解或持续缓解。
核心结论
- TIR是估算就诊间未观测疾病活动度的直观方法,且是RA结局的有效预测指标。
研究设计与样本
- 基于捷克ATTRA-RA注册库的前瞻性研究,纳入2010年起2618例开始抗TNF治疗的RA患者,随访至2020年或停药。
主要发现
- 治疗前6个月56%患者无缓解(TIR=0),22%达持续缓解(TIR=1),22%为点缓解(0<TIR<1)。
- EULAR良好应答者和中度/无应答者处于缓解的时间分别为64±42%和6±18%。
- TIR与DAS28-CRP、SDAI、HAQ、PGA及PhGA相关(P<0.0001)。
- 3个月和6个月TIR预测13个月和19个月时缓解(SDAI≤3.3)及无残疾(HAQ<0.5)优于点缓解或持续缓解。
关键数值与推荐
- 缓解定义为SDAI≤3.3,无残疾定义为HAQ<0.5。
- TIR计算仅需两次连续疾病活动度值,并提供了在线计算器(https://www.medevio.cz/tir-calculator/)。
临床怎么用
- 临床中可利用两次连续DAS28-ESR通过线性插值计算TIR,以估算就诊间疾病活动度。
- 早期(3个月和6个月)TIR可帮助预测远期缓解和无残疾状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Achieving targeted disease activity (DA) is the primary therapeutic strategy in RA. Point measurements of DA are done at out-patient visits, however true DA between visits remains unobserved. This study sought to describe and validate a new outcome measure, i.e. time in remission (TIR). METHODS: Patients were enrolled in the Czech ATTRA-RA registry. TIR was calculated using linear interpolation of the DAS28-ESR determined at outpatient visits. Correlation coefficients were computed between TIR and DAS28-CRP, HAQ, Simple Disease Activity Index (SDAI), patient global assessment (PGA) and physician global assessment (PhGA). Using logistic regression, TIR was used as a predictor of remission (SDAI ≤3.3) and non-disability (HAQ <0.5). The predictive value of TIR was compared with point and sustained remission using the cross-validated area under receiver-operating curves. RESULTS: Since 2010, 2618 RA patients started anti-TNF therapy and were followed until 2020 or until treatment discontinuation. During the first 6 months of therapy, 56% of patients had no remission (TIR = 0), and 22% of patients reached sustained remission (TIR = 1), while 22% of patients had point remissions with 0 < TIR < 1. EULAR good responders and moderate/non-responders spent 64 ± 42% and 6 ± 18% of time in remission, respectively. The mean TIR grew during the follow-up and was correlated with DAS28-CRP, SDAI, HAQ, PGA, and PhGA (P < 0.0001). TIR at 3 and 6 months predicted remission (SDAI ≤3.3) and non-disability (HAQ <0.5) at 13 and 19 months better than point or sustained remission. CONCLUSIONS: TIR is an intuitive way of estimating unobserved DA between scheduled visits; its calculation only requires two consecutive DA values (https://www.medevio.cz/tir-calculator/). TIR is a valid predictor of RA outcomes.
引用
- Tužil J, Mlčoch T, Závada J, et al. Time in remission as an alternative outcome measure for rheumatoid arthritis: a 10-year prospective study of 2618 new users of anti-TNF. Rheumatology (Oxford). 2022. PMID: 34599798. doi:10.1093/rheumatology/keab737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。